Everest Medicines Acquires Development Rights for VIZZ® in Greater China from LENZ Therapeutics
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
Image: Benzinga
LENZ Therapeutics has announced that Everest Medicines acquired the rights to develop and commercialize VIZZ® (LNZ100), an eye drop treatment for presbyopia, in Greater China. The deal includes potential milestone payments of up to $85 million and is expected to address unmet medical needs in the region.
- 01Everest Medicines acquired rights to develop and commercialize VIZZ® (LNZ100) in Greater China, including mainland China, Hong Kong, Macao, and Taiwan.
- 02LENZ Therapeutics is eligible for up to $85 million in regulatory and sales milestone payments as part of the agreement.
- 03The New Drug Application for LNZ100 was submitted in September 2025, with approval expected in Q1 2027.
- 04VIZZ® is the first FDA-approved aceclidine-based eye drop for treating presbyopia, impacting 1.8 billion people globally.
- 05Everest Medicines aims to provide a novel, non-invasive treatment option for the growing presbyopia patient population.
Advertisement
In-Article Ad
LENZ Therapeutics, Inc. announced that Everest Medicines has entered into an Asset Purchase Agreement to acquire the rights for VIZZ® (LNZ100), the first aceclidine-based eye drop for presbyopia, in Greater China. This agreement includes the transfer of rights and obligations from Corxel Pharmaceuticals, which previously held the licensing agreement. LENZ is positioned to receive up to $85 million in regulatory and sales milestones, alongside tiered royalties on net sales. The New Drug Application for LNZ100 was submitted to the National Medical Products Administration of China in September 2025, with approval anticipated in the first quarter of 2027. Yifang Wu, Chairman of Everest Medicines, emphasized the importance of LNZ100 in addressing significant unmet needs in non-invasive presbyopia treatments. Eef Schimmelpennink, CEO of LENZ, expressed optimism about collaborating with Everest to advance the commercialization of this innovative therapy.
Advertisement
In-Article Ad
The acquisition aims to enhance access to innovative treatments for presbyopia in Greater China, addressing a significant healthcare need.
Advertisement
In-Article Ad
Reader Poll
What do you think about the potential of VIZZ® as a treatment for presbyopia?
Connecting to poll...
Read the original article
Visit the source for the complete story.